🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Jemincare clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Jemincare as lead sponsor. Synced 26 Sep 2026
10Current trials
9Recruiting now
7Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Jemincare is the lead sponsor of 10 current clinical trials in our China register. 9 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are JMKX001899, JYB1904 and Carboplatin. The most-studied condition is Chronic Spontaneous Urticaria.

ClinicalTrials.gov trials by status

  • Recruiting990%
  • Not yet open110%

Trials by phase

  • Phase 1550%
  • Phase 2330%
  • Phase 3220%
01

Clinical trials sponsored by Jemincare

10 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Trial of JMKX003801 in Healthy Participants
NCT06549309 · ClinicalTrials.gov ↗ · Healthy
Phase 1 Recruiting 2024-08 China
Trial of JYB1904 in Chronic Spontaneous Urticaria.
NCT06509334 · ClinicalTrials.gov ↗ · Chronic Spontaneous Urticaria
Phase 2 Recruiting 2024-08 China
A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma
NCT06321250 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma Metastatic
Phase 1 Recruiting 2024-03 China
A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors
NCT07208136 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Phase 1 Recruiting 2025-10 China
Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.
NCT07402213 · ClinicalTrials.gov ↗ · Chronic Spontaneous Urticaria
Drug: JYB1904
Phase 3 Recruiting 2026-03 China
A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation
NCT06946927 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer)
Phase 1 Recruiting 2025-06 China
Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
NCT06664125 · ClinicalTrials.gov ↗ · Hyperphosphatemia
Phase 2 Recruiting 2024-12 China
Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT06800651 · ClinicalTrials.gov ↗ · ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Phase 2 Recruiting 2025-03 China
A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
NCT06740019 · ClinicalTrials.gov ↗ · Malignant Pleural Effusions (Mpe)
Phase 1 Recruiting 2024-12 China
Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC
NCT07242274 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer)
Phase 3 Not yet open 2025-12 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Jemincare trials

7 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Jemincare trials

9 conditions
Chronic Spontaneous Urticaria2Healthy1Renal Cell Carcinoma Metastatic1Advanced Solid Tumors1NSCLC (Non-small Cell Lung Cancer)1NSCLC (Advanced Non-small Cell Lung Cancer)1Hyperphosphatemia1ADPKD (Autosomal Dominant Polycystic Kidney Disease)1Malignant Pleural Effusions (Mpe)1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China109

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Chronic Spontaneous Urticaria

SponsorTrials
Novartis Pharmaceuticals6
Celldex Therapeutics3
Chengdu Suncadia Medicine1

Sponsors with the most current trials registered for this condition.

06

Questions about Jemincare trials

How many clinical trials does Jemincare sponsor?

Jemincare is the lead sponsor of 10 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Jemincare trials recruiting?

Yes. 9 of its 10 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Jemincare testing?

Its current trials name 7 drugs and biologicals as interventions. The most frequent are JMKX001899 (2), JYB1904 (2), Carboplatin (1), Docetaxel (1) and IN10018 (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.